Last reviewed · How we verify
Raltegravir, lopinavir, ritonavir
Raltegravir, lopinavir, ritonavir is a Antiretroviral combination therapy (integrase inhibitor + protease inhibitors) Small molecule drug developed by Allina Health System. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients. Also known as: Isentress, Kaletra.
This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase (raltegravir) and protease (lopinavir/ritonavir) enzymes essential for viral reproduction.
This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase (raltegravir) and protease (lopinavir/ritonavir) enzymes essential for viral reproduction. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naïve patients.
At a glance
| Generic name | Raltegravir, lopinavir, ritonavir |
|---|---|
| Also known as | Isentress, Kaletra |
| Sponsor | Allina Health System |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + protease inhibitors) |
| Target | HIV integrase, HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor that prevents HIV DNA from integrating into the host genome. Lopinavir and ritonavir are protease inhibitors that block the HIV protease enzyme required for processing viral proteins; ritonavir also acts as a pharmacokinetic booster to increase lopinavir levels. Together, they suppress viral replication through complementary mechanisms.
Approved indications
- HIV-1 infection in treatment-experienced patients
- HIV-1 infection in treatment-naïve patients
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Lipid abnormalities
- Hepatotoxicity
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raltegravir, lopinavir, ritonavir CI brief — competitive landscape report
- Raltegravir, lopinavir, ritonavir updates RSS · CI watch RSS
- Allina Health System portfolio CI
Frequently asked questions about Raltegravir, lopinavir, ritonavir
What is Raltegravir, lopinavir, ritonavir?
How does Raltegravir, lopinavir, ritonavir work?
What is Raltegravir, lopinavir, ritonavir used for?
Who makes Raltegravir, lopinavir, ritonavir?
Is Raltegravir, lopinavir, ritonavir also known as anything else?
What drug class is Raltegravir, lopinavir, ritonavir in?
What development phase is Raltegravir, lopinavir, ritonavir in?
What are the side effects of Raltegravir, lopinavir, ritonavir?
What does Raltegravir, lopinavir, ritonavir target?
Related
- Drug class: All Antiretroviral combination therapy (integrase inhibitor + protease inhibitors) drugs
- Target: All drugs targeting HIV integrase, HIV protease
- Manufacturer: Allina Health System — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-experienced patients
- Indication: Drugs for HIV-1 infection in treatment-naïve patients
- Also known as: Isentress, Kaletra
- Compare: Raltegravir, lopinavir, ritonavir vs similar drugs
- Pricing: Raltegravir, lopinavir, ritonavir cost, discount & access